SUPER-1 is a 52-week (26-week main phase plus 26-week extension phase), phase 3, treat-to-target trial investigating the efficacy and safety of once-weekly GZR4 versus once-daily insulin glargine U100 ...

Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.

The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 -- ...

The FDA just approved Awiqli, a once-weekly insulin treatment for type 2 diabetes. Awiqli allows patients to shift from daily injections. The effectiveness, safety, and side effects are similar to ...

The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct ...

Data from the ONWARDS clinical trial program supported the efficacy of once-weekly insulin icodec-abae compared with daily basal insulin. The Food and Drug Administration (FDA) has approved Awiqli ® ...

Recent advances in insulin formulation have brought forth once-weekly therapies that promise improved adherence and consistent glycaemic control for people with diabetes. Traditional basal insulin ...

PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Insulin efsitora was noninferior to once-daily insulins ...

Awiqli (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli offers adults with type 2 diabetes an alternative to daily basal insulin injections, ...